Interstitial lung disease in polymyositis and dermatomyositis

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Interstitial lung disease (ILD) frequently complicates polymyositis (PM) and dermatomyositis (DM), contributing significantly to patient morbidity.
• The exact etiology of ILD in PM/DM remains unknown but is strongly linked to autoimmune processes.
• Heterogeneous clinical presentations and differing immunologic/histopathologic findings suggest varied immunopathogenetic mechanisms in PM/DM-associated ILD.

Purpose of the Study:

• To review clinicopathologic and immunologic findings in ILD associated with PM/DM.
• To discuss recent advancements in the classification, autoantibody identification, and therapeutic strategies for PM/DM-ILD.
• To highlight critical research needs, particularly clarifying the immunopathogenesis of severe ILD forms and optimizing treatment.

Main Methods:

• Literature review of clinicopathologic and immunologic studies.
• Analysis of recent advances in classification systems for ILD in PM/DM.
• Examination of current research on autoantibodies and treatment modalities.

Main Results:

• ILD is a common and serious comorbidity in PM/DM patients.
• Significant heterogeneity exists in the immunologic and histopathologic features of PM/DM-ILD.
• Advances in autoantibody research and classification are emerging.

Conclusions:

• Understanding the diverse immunopathogenesis of PM/DM-ILD is crucial.
• Further research is needed to clarify mechanisms, especially in rapidly progressive forms.
• Establishing optimal therapeutic strategies for severe PM/DM-ILD is a priority.